July 8, 2019 - Fierce Pharma
Roche and Spark Therapeutics’ road to a $4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four times. Now, in order to get all its regulatory ducks in a row, Roche is moving its own deal-close deadline back as well.
July 9, 2019 - BioPharma-Reporter
Century Therapeutics advances its allogeneic cell therapy platform created programs to the clinic after a $250m in financing led by Bayer. The company is focused on developing allogeneic immune cell therapies for cancer and was founded by Versant Ventures, alongside a partnership with Fujifilm Cellular Dynamics (FCDI). The two companies, alongside Bayer, have contributed $250m (€221.22) in financing to the biotech, which came out of stealth mode on the announcement of funding.
July 10, 2019 - BioPharma Dive
Amneal Pharmaceuticals will restructure its business and cut costs in a plan aimed at saving the company about $50 million a year, it
said Wednesday
. Amneal also slashed its estimate for core profits in 2019, forecasting between $425 million and $475 million in adjusted earnings before interest, taxes and other expenses. That's a sharp cut to
earlier estimates
of between $600 million and $650 million, sending shares in the company down by a third Wednesday.
July 10, 2019 - Contract Pharma
Orexo AB
has signed an agreement granting
Mundipharma Pty Ltd.
(Mundipharma Australia) the exclusive rights to commercialize Orexo's lead product, Zubsolv, for the treatment of opioid dependence, in Australia and New Zealand. Mundipharma Australia supported Orexo in obtaining marketing authorization for Zubsolv in Australia. Orexo will now be responsible for product supply and Mundipharma Australia will take responsibility for commercialization of Zubsolv in Australia and New Zealand. Orexo will receive royalties on future sales and the launch is expected 1H20.
